Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study

VACCINEX, INC.

Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.
Database lock expected in June; key outcomes including safety, FDG-PET, and plasma GFAP biomarkers to be reported in July.
Pepinemab targets SEMA4D to inhibit astrocyte reactivity and neuroinflammation, a differentiated mechanism vs. anti-amyloid antibodies.
Study funded by $4.75M from ADDF and $0.75M grant from Alzheimer's Association.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.